BACKGROUND Polycystic ovary syndrome (PCOS) is associated with cardiometabolic
disease, but recent systematic reviews and meta-analyses of longitudinal studies that …

Background Type 2 diabetes mellitus (T2DM) is a global epidemic associated with
increased health expenditure, and low quality of life. Many non-genetic risk factors have …

Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of plasminogen
activators (PAs) and is therefore an important inhibitor of the plasminogen/plasmin system …

Chronic wounds are becoming an increasingly common clinical problem due to an aging
population and an increased incidence of diabetes, atherosclerosis, and venous …

Discovery of biosensors has acquired utmost importance in the field of healthcare. Recent
advances in biological techniques and instrumentation involving nanomaterials, surface …

Diet has direct and indirect effects on health through inflammation and the gut microbiome.
We investigated total dietary inflammatory potential via the literature-derived index (Dietary …

Background Small studies have implicated plasminogen activator inhibitor-1 (PAI-1) as a
predictor of cardiovascular events; however, these findings have been inconsistent. We …

Cardiovascular disease (CVD) is the leading cause of death globally. Risk assessment is
crucial for identifying at-risk individuals who require immediate attention as well as to guide …

Background Plasminogen activator inhibitor type 1 (PAI‐1) plays an essential role in the
fibrinolysis system and thrombosis. Population studies have reported that blood PAI‐1 levels …

Abstract Plasminogen activator inhibitor 1 (PAI-1) is a functional biomarker of the metabolic
syndrome. Previous studies have demonstrated that PAI-1 is a mechanistic contributor to …